trazpiroben trazpiroben trazpiroben (developmental code name tak-906) is a dopamine antagonist drug which was under development for the treatment of gastroparesis. it acts as a peripherally selective dopamine d2 and d3 receptor antagonist. the drug has been found to strongly increase prolactin levels in humans, similarly to other peripherally selective d2 receptor antagonists like domperidone. clinical development of trazpiroben was discontinued before april 2022. trazpiroben was originated by altos therapeutics and was under development by takeda oncology. trazpirobenclinical dataother namestak-906; atc-1906drug classdopamine antagonistidentifiers iupac name 3-decan-3-yl]methyl]benzoic acid cas number1352993-39-5pubchem cid54768846chemspider81367274uniifh87h57q4ychemblchembl4650340chemical and physical dataformulac31h39n3o4molar mass517.670 g·mol−13d model (jsmol)interactive image smiles c1ccc(cc1)n2cn(c(=o)c23ccn(cc3)cccc(=o)c4=cc=cc=c4)cc5=cc(=cc=c5)c(=o)o inchi inchi=1s/c31h39n3o4/c35-28(25-10-3-1-4-11-25)15-8-18-32-19-16-31(17-20-32)30(38)33(23-34(31)27-13-5-2-6-14-27)22-24-9-7-12-26(21-24)29(36)37/h1,3-4,7,9-12,21,27h,2,5-6,8,13-20,22-23h2,(h,36,37)key:bdxjyaaylztlek-uhfffaoysa-n